HSN002066

**HSN002066** is a preclinical **small molecule** anticancer agent being developed by **Chongqing Joywin** through its subsidiary **Huasen Inno** for **tumor immunotherapy**, with the stated goal of improving low response rates to cancer immunotherapy. Publicly available 2024 AACR-related disclosures identify HSN002066 as a **novel, highly selective PARP7 inhibitor** with improved potency and selectivity, supporting an immuno-oncology mechanism in which inhibition of PARP7 may enhance type I interferon signaling and antitumor immune responses. The program appears to remain in the **preclinical** stage, and no brand name, dosage form, route, or formal clinical indication has been publicly disclosed.